Scribe Therapeutics kicked off trading after pricing an upsized initial public offering focused on CRISPR-based therapies for cardiovascular and metabolic diseases. The company raised about $129 million from an offering of 8.6 million shares at $15 each, beginning Nasdaq trading under ticker SCTX. The IPO pricing at the top end of its range and the sharp first-day pop underscored renewed investor appetite for gene-editing platforms. Scribe’s funding is intended to support early clinical progress and pipeline development, with the company emphasizing in vivo gene editing as it expands beyond rare-disease-only narratives. The transaction adds to a streak of strong public-market openings for gene and cell therapy companies, where investors are paying for platform credibility and near-term readouts.